Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -0.27%91 Return-on-Tangible-Equity is 6.91% as of Mar. 2026, which is 38% below its 10-year median of 11.11. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 901 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 60.93% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Birzeit Pharmaceutical Co's annualized net income for the quarter that ended in Mar. 2026 was $7.91 Mil. Birzeit Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $114.51 Mil. Therefore, Birzeit Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 6.91%.
The historical rank and industry rank for Birzeit Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
XPAE:BPC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.97 Med: 11.11 Max: 16.9
Current: 11.48
During the past 13 years, Birzeit Pharmaceutical Co's highest Return-on-Tangible-Equity was 16.90%. The lowest was 4.97%. And the median was 11.11%.
XPAE:BPC's Return-on-Tangible-Equity is ranked better than 60.93% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs XPAE:BPC: 11.48
Birzeit Pharmaceutical Co (XPAE:BPC) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Birzeit Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Birzeit Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Birzeit Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co Return-on-Tangible-Equity Chart
XPAE:BPC vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.91% mean?
Birzeit Pharmaceutical Co (XPAE:BPC) has a Return-on-Tangible-Equity of 6.91% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 38% below median its historical median of 11.11. Over the past decade, Birzeit Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 4.97 to 16.90. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #352 out of 901 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Birzeit Pharmaceutical Co's Return-on-Tangible-Equity too high?
Birzeit Pharmaceutical Co's current Return-on-Tangible-Equity of 6.91% is 38% below median its 10-year median of 11.11. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 16.90. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Birzeit Pharmaceutical Co's value of 6.91% is 12.5% below this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #352 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #352 out of 901 companies for Return-on-Tangible-Equity. This puts Birzeit Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Birzeit Pharmaceutical Co's value of 6.91% is 12.5% below this benchmark. Historically, Birzeit Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 4.97 to 16.90 over the past decade. While the company's 10-year median is 11.11 vs. the industry median of 7.90, Birzeit Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Return-on-Tangible-Equity of 6.91% is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Return-on-Tangible-Equity is 6.91%, which is 38% below median its own 10-year median of 11.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current Return-on-Tangible-Equity is 6.91%, which is 38% below median its 10-year median of 11.11 and 12.5% below the Drug Manufacturers industry median of 7.90. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Return-on-Tangible-Equity is 6.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Return-on-Tangible-Equity: 6.91% (38% below median its 10-year median of 11.11)
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 12.5% below the Drug Manufacturers median (#352 of 901)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
